Bibliometric analysis of studies on drug safety in the elderly with multiple diseases
10.12173/j.issn.1005-0698.202408045
- VernacularTitle:多病共患老年人群安全用药研究的文献计量学分析
- Author:
Limin LI
1
;
Wenyu WU
1
;
Fenfang WEI
1
;
Jianru WU
1
Author Information
1. 深圳市药物警戒和风险管理研究院(广东 深圳 518000)
- Publication Type:Journal Article
- Keywords:
The elderly;
Multimorbidity;
Drug safety;
Bibliometrics;
Visual analysis
- From:
Chinese Journal of Pharmacoepidemiology
2024;33(12):1425-1435
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the current status,research hotspots and development trends of safe medication in the global elderly with multimorbidity,and to provide theoretical reference for research in this field.Methods CNKI,Yiigle and Web of Science were searched for studies on medication safety in the elderly with multimorbidity.The search time was from the establishment of the database to May 1,2024.R language and other software were used to visually analyze the annual number of publications,institutions,and the clustering,refinement,and hotspots and trends of keywords.Results A total of 20 Chinese articles and 654 English articles were included.There is little global attention to this field,and cooperation between institutions needs to be further strengthened.General practice,general practitioners,Beers criteria,polypharmacy,primary care,inappropriate prescribing,medication adherence,deprescribing are the key directions of concern in this field globally.At present,most of the Chinese literature is from the perspective of clinical practice,such as medication management and intervention measures.The English literature mainly focuses on the safety of chronic disease medication,quality of life,medication adherence,and risk of chronic disease medication from the patients'perspective.With the increasing popularity of deprescribing,future research in this area of medication management will place greater emphasis on personalized and precision medicine.Conclusions The study of drug safety in the elderly with multimorbidity needs to establish and improve the primary care mechanism,improve the adherence of patients,and use relevant standards to effectively evaluate the safety and potential risks of polypharmacy in the elderly with multimorbidity,identify potentially inappropriate drugs and deprescribing,to reduce the risk of adverse drug reactions,and to further improve the quality of life and reduce medical costs in the elderly with multimorbidity.
